Zymeworks
2 known investors
Zymeworks develops novel medicines for patients with difficult-to-treat diseases using proprietary platforms and in-house R&D capabilities. The company manages a portfolio of healthcare assets across multiple therapeutic indications.
BiotechDigital HealthMedical Devices
Investors · 2
In the news
- Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Runfinance.yahoo.com · 2026